Equities Analysts Issue Forecasts for PVLA FY2025 Earnings

Palvella Therapeutics (NASDAQ:PVLA - Free Report) - Equities research analysts at Chardan Capital issued their FY2025 EPS estimates for shares of Palvella Therapeutics in a report issued on Wednesday, April 9th. Chardan Capital analyst G. Livshits forecasts that the company will post earnings of ($2.43) per share for the year. Chardan Capital has a "Buy" rating and a $50.00 price objective on the stock. The consensus estimate for Palvella Therapeutics' current full-year earnings is ($3.69) per share. Chardan Capital also issued estimates for Palvella Therapeutics' FY2026 earnings at ($3.06) EPS.

Several other brokerages have also commented on PVLA. Stifel Nicolaus assumed coverage on Palvella Therapeutics in a research report on Wednesday, March 26th. They set a "buy" rating and a $45.00 price objective on the stock. HC Wainwright reissued a "buy" rating and set a $38.00 price target on shares of Palvella Therapeutics in a research note on Tuesday, April 1st. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $39.00 price objective on shares of Palvella Therapeutics in a research note on Wednesday, February 26th. Jones Trading began coverage on shares of Palvella Therapeutics in a research report on Tuesday, March 25th. They issued a "buy" rating and a $45.00 target price on the stock. Finally, TD Cowen initiated coverage on Palvella Therapeutics in a research note on Wednesday, February 5th. They set a "buy" rating and a $44.00 price objective on the stock. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Palvella Therapeutics presently has an average rating of "Buy" and a consensus target price of $44.43.

Palvella Therapeutics Price Performance

NASDAQ:PVLA traded down $0.04 during midday trading on Monday, hitting $24.36. The company had a trading volume of 43,015 shares, compared to its average volume of 66,473. The stock has a fifty day simple moving average of $23.45. Palvella Therapeutics has a 52-week low of $6.20 and a 52-week high of $29.27. The firm has a market cap of $268.42 million, a P/E ratio of -2.01 and a beta of 0.10.

Insider Activity

In other Palvella Therapeutics news, Director George M. Jenkins purchased 2,500 shares of the stock in a transaction on Wednesday, April 9th. The stock was acquired at an average price of $20.13 per share, with a total value of $50,325.00. Following the transaction, the director now directly owns 183,171 shares of the company's stock, valued at approximately $3,687,232.23. This trade represents a 1.38 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 6.39% of the company's stock.

Hedge Funds Weigh In On Palvella Therapeutics

Hedge funds have recently made changes to their positions in the business. Citadel Advisors LLC bought a new stake in Palvella Therapeutics in the fourth quarter valued at $125,000. Toronto Dominion Bank bought a new position in Palvella Therapeutics in the fourth quarter worth about $159,000. Geode Capital Management LLC purchased a new stake in Palvella Therapeutics in the fourth quarter worth about $171,000. Cresset Asset Management LLC bought a new stake in Palvella Therapeutics during the 4th quarter valued at approximately $251,000. Finally, Renaissance Technologies LLC purchased a new position in shares of Palvella Therapeutics during the 4th quarter worth approximately $256,000. 40.11% of the stock is owned by hedge funds and other institutional investors.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.